+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Matrix Metalloproteinases in Myocardial Infarction and Heart Failure



Matrix Metalloproteinases in Myocardial Infarction and Heart Failure



Progress in Molecular Biology and Translational Science 147: 75-100



Cardiovascular disease is the leading cause of death, accounting for 600,000 deaths each year in the United States. In addition, heart failure accounts for 37% of health care spending. Matrix metalloproteinases (MMPs) increase after myocardial infarction (MI) and correlate with left ventricular dysfunction in heart failure patients. MMPs regulate the remodeling process by facilitating extracellular matrix turnover and inflammatory signaling. Due to the critical role MMPs play during cardiac remodeling, there is a need to better understand the pathophysiological mechanism of MMPs, including the biological function of the downstream products of MMP proteolysis. Future studies developing new therapeutic targets that inhibit specific MMP actions to limit the development of heart failure post-MI are warranted. This chapter focuses on the role of MMPs post-MI, the efficiency of MMPs as biomarkers for MI or heart failure, and the future of MMPs and their cleavage products as targets for prevention of post-MI heart failure.

(PDF emailed within 0-6 h: $19.90)

Accession: 059948019

Download citation: RISBibTeXText

PMID: 28413032

DOI: 10.1016/bs.pmbts.2017.02.001


Related references

Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure. Zhonghua Yi Xue Za Zhi 86(24): 1693-1696, 2006

Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119(18): 2471-2479, 2009

Differential release of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in patients following alcohol induced myocardial infarction. Circulation 104(17 Supplement): II 305, October 23, 2001

TNF-a and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. American Journal of Physiology 282(4): 288-H1295, 2002

TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. American Journal of Physiology. Heart and Circulatory Physiology 282(4): H1288-H1295, 2002

Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Annals of Medicine 33(9): 623-634, 2002

The expression and significance of activator protein-1 and matrix metalloproteinases in the human heart post acute myocardial infarction. Zhonghua Nei Ke Za Zhi 48(3): 205-207, 2009

A history of prior myocardial infarction was independently predictive of mortality but not of recurrent myocardial infarction or heart failure hospitalization in 5477 patients with acute myocardial infarction complicated by cardiac failure. Journal of the American College of Cardiology 39(5 Supplement A): 153A, March 6, 2002

Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovascular Therapeutics 30(1): 31-41, 2012

Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction. Journal of Surgical Research 172(1): 59-67, 2012

Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio. Chinese Medical Journal 126(11): 2149-2156, 2014

Viable fibroblast matrix patch induces angiogenesis and increases myocardial blood flow in heart failure after myocardial infarction. Tissue Engineering. Part A 16(10): 3065-3073, 2011

Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 125(2): 271-279, 2012

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. International Journal of Cardiology 151(2): 237-239, 2012

Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. Journal of Cardiac Failure 12(1): 66-72, 2006